A mouse model of liver cancer caused by chronic HBV infection.

On January 15th, the journal Nature Communications published an online research paper on "The Field Zhigang Group of the National Laboratory of Natural Immunology and Chronic Diseases of the Chinese Academy of Sciences, the National Research Center for Microscale Matter Science stomping", "The Adaptive Ofere-Group of The Siquescellular-Carcellinoma in HBs Ag-t-mice" published online in the journal Nature Communications.
the study found that TIGIT inhibitory pathways in genetically modified mice maintained the tolerance of CD8-T cells to HBV, which allowed HBV genetically modified mice (HBV carrying models) to develop chronic inflammation into the liver and eventually develop into liver cancer.
chronic hepatitis B (chronic HBV) infection can lead to chronic hepatitis, cirrhosis, and even liver cancer.
and studies of chronic HBV infection have been lacking suitable mouse models.
liver is a special immune-tolerant organ, the liver of immune cells mainly show an immune tolerance state.
in clinicalh-based HBV carriers and HBV genetically modified mice, CD8-T cells in the liver were immunosuppressed due to high expression inhibitory receptors and did not produce liver damage, while when the liver immune-tolerant environment was broken and immune cells were activated, the immune response caused by the removal of the virus could lead to liver inflammation.
the study found that HBV genetically modified (HBs-tg) mice with high expression inhibitory receptor TIGIT in the liver can cause chronic hepatitis in mice by continuously blocking TIGIT inhibitory pathways.
immunize mice with HBV surface antigens after TIGIT blocking, which can produce liver cancer.
to explore the mechanism, the researchers found an increase in the number of CD8-T cells in the liver of HBs-tg mice after TIGIT blocking, increased activation, and the appearance of antigen-specific CTLs.
the HBs-tg mice that removed CD8-T cells had significantly reduced liver damage after blocking TIGIT, and if HBs-tg mice blocked by TIGIT were removed from CD8-T cells during vaccine immunity, they would not develop into liver cancer.
, the study found that the TIGIT inhibitory pathway maintained the tolerance of CD8-T cells in HBV-carrying mice, and successfully established a mouse model of liver cancer caused by chronic HBV infection, which provided an appropriate animal platform for further in-depth study of the prevention and treatment of HBV-related liver cancer.
research work has been supported by the National Key Research and Development Program, the National Natural Science Foundation of China, the leading projects of the Chinese Academy of Sciences and major special projects.
the newsletter is written by Tian Zhigang and the first author is Zong Wei.
The diagnosis and prognosis of liver failure has the Chinese standard from Zhejiang University Medical College affiliated first hospital (hereinafter referred to as Zhejiang University Hospital) was informed that the team of experts in Zhejiang University, 12 well-known university hospital liver disease centers in the United Nations, after 6 years of research, established a slow and acute liver failure (ACLF) diagnosis and prognosis of the Chinese standard (COSSH-ACLF). On 8 December
, the research results were published in GUT, the leading international journal in the field of digestive diseases, under the title "Development of the diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure" and was invited to publish in Gut, the most influential paper. Professor Li Jun of the Li Lanxuan Academician's team at Zhejiang University,
, said that ACLF is an acute liver function deterioration based on chronic liver disease, with a short-term fatality rate of 50%-90%.
however, at present, there is still a lack of uniform diagnostic standards for ACLF in the world.
on the one hand, the study of ACLF in Europe and the United States is mainly based on the alcohol liver-based population, did not include the hepatitis B-based disease population.
and most of the patients with liver failure in the Asia-Pacific region have the basis of hepatitis B disease, and European standards have applicable limitations.
on the other hand, the existing Asia-Pacific ACLF diagnosis and treatment guidelines, due to the lack of forward-looking large sample research, has not been widely recognized in the international community.
therefore, it is particularly important to establish ACLF definition and diagnostic prognosis standard sizing in line with international norms, which are based on hepatitis B population.
Since 2012, the team of Li Lanxuan academicians of Zhejiang University Hasuten has conducted multi-center prospective research in 12 centers across the country, covering 2,638 cases of liver disease in China.
results show that patients with hepatitis B ACLF have unique clinical characteristics different from those with alcoholic liver ACLF in Europe and america: First, chronic hepatitis B patients with or without cirrhosis, are likely to progress into ACLF;
based on the above findings, the scientists believe that the short-term mortality rate of patients with single liver failure (TB-12mg/dl) and INR of 1.5 slow hepatitis B patients, whether or not combined with cirrhosis, should be diagnosed with ACL F, and the Chinese diagnostic criteria for hepatitis B ACLF should be proposed.
Li Lanxuan said that The Chinese diagnostic standards will make the early diagnosis of ACLF in the hepatitis B population more sensitive and provide a new scientific basis for timely treatment of the population.
"At least 20 percent of patients are diagnosed with ACLF and give them the opportunity to receive timely and comprehensive treatment to reduce the fatality rate."
" Source: Zhejiang News, China University of Science and Technology.